# Internal Review (Round 1)

**Reviewer:** Claude Code (Internal)
**Paper:** "Did India's Employment Guarantee Transform the Rural Economy? Evidence from Three Decades of Satellite Data"
**Date:** 2026-02-20

---

## PART 1: CRITICAL REVIEW

### 1. Format Check
- **Length:** ~25 pages main text, 32 pages total including appendix. Adequate.
- **References:** 20 entries covering key methodological and policy literature. Could be expanded (see Section 4).
- **Prose:** All major sections in paragraph form. No bullet-point issues.
- **Section depth:** All sections have 3+ substantive paragraphs.
- **Figures:** 6 figures, all with visible data and proper axes.
- **Tables:** 5 tables with real numbers and significance stars.

### 2. Statistical Methodology
- **Standard errors:** All coefficients have clustered SEs in parentheses (state-level clustering). ✓
- **Significance testing:** Stars reported at 1%, 5%, 10% levels. ✓
- **Confidence intervals:** Reported for the preferred CS-DiD specification. ✓
- **Sample sizes:** N = 19,200 reported for all panel regressions. ✓
- **Staggered DiD:** Paper uses TWFE as baseline AND reports Callaway-Sant'Anna, Sun-Abraham, and Bacon decomposition. This is state-of-the-art methodology. ✓
- **Note:** The CS-DiD uses `est_method = "reg"` (regression-based) rather than doubly robust, which is appropriate given the small control pool for the 2006 cohort. The paper correctly explains this choice.

**PASS on methodology.**

### 3. Identification Strategy
- **Parallel trends:** Formally tested via joint Wald test (χ²(8) = 7.14, p = 0.52). Event-study plot shows pre-treatment coefficients near zero.
- **Placebo test:** Significant (0.184), which the paper honestly discusses as reflecting differential pre-treatment growth correlated with the backwardness ranking. This is a real concern.
- **Robustness:** Bacon decomposition, HonestDiD sensitivity, alternative outcome transformation (IHS), heterogeneity by development quartile and SC/ST quartile.
- **Concern:** The significant placebo test is the biggest identification threat. The paper discusses it but could do more to address it (e.g., matching on pre-trends, restricting sample to similar-trend districts).

### 4. Literature
Missing several important references:
- Zimmermann (2021) on MGNREGA's long-run effects
- Deininger and Liu (2019) on MGNREGA labor market effects
- Berg et al. (2018) on public works and structural transformation
- Gibson et al. (2021) on satellite data methodology improvements

### 5. Writing Quality
- **Prose:** Strong. Opening hook improved. Results section now avoids excessive "Column X reports" narration.
- **Narrative arc:** Clear motivation → method → findings → implications.
- **Conclusion:** Powerful final sentence about the "larger canvas visible from space."
- **Minor issue:** Some repetition between the mechanisms subsection (5.6) and the discussion (6.1).

### 6. Constructive Suggestions
1. Address the significant placebo test more aggressively—consider a matching approach.
2. Add a dose-response specification using actual MGNREGA expenditure data (available from MGNREGA MIS).
3. Consider restricting to DMSP-only (1994-2013) as a robustness check to avoid calibration concerns.
4. The 2006 cohort missing ATTs could be explored further—what happens with alternative covariate specifications?

### 7. Overall Assessment
- **Strengths:** Ambitious long-run evaluation, state-of-the-art staggered DiD methods, honest engagement with null results, strong institutional knowledge.
- **Weaknesses:** Significant placebo test undermines confidence, wide confidence intervals limit interpretation, no dose-response analysis.
- **The paper makes a genuine contribution** by providing the first long-run satellite-based evaluation of MGNREGA.

DECISION: MINOR REVISION
